vs
摩托罗拉系统（ISSC）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
REGENXBIO Inc.的季度营收约是摩托罗拉系统的1.4倍（$30.3M vs $21.8M），摩托罗拉系统净利率更高（18.6% vs -221.3%，领先240.0%），REGENXBIO Inc.同比增速更快（43.0% vs 36.6%），摩托罗拉系统自由现金流更多（$7.0M vs $-52.8M），过去两年摩托罗拉系统的营收复合增速更高（42.5% vs 39.4%）
摩托罗拉系统是一家美国科技企业，专注于研发供应安全防护相关产品与服务，总部位于伊利诺伊州芝加哥。公司主营关键通信、视频安防与指挥中心技术，相关产品与服务面向公共安全机构及各类企业。公司于2011年从原摩托罗拉拆分而来，是原摩托罗拉的合法继承主体，原摩托罗拉手机业务拆分后成为摩托罗拉移动。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
ISSC vs RGNX — 直观对比
营收规模更大
RGNX
是对方的1.4倍
$21.8M
营收增速更快
RGNX
高出6.4%
36.6%
净利率更高
ISSC
高出240.0%
-221.3%
自由现金流更多
ISSC
多$59.8M
$-52.8M
两年增速更快
ISSC
近两年复合增速
39.4%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $21.8M | $30.3M |
| 净利润 | $4.1M | $-67.1M |
| 毛利率 | 54.5% | — |
| 营业利润率 | 28.9% | -190.0% |
| 净利率 | 18.6% | -221.3% |
| 营收同比 | 36.6% | 43.0% |
| 净利润同比 | 451.4% | -31.2% |
| 每股收益（稀释后） | $0.22 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ISSCRGNX
| Q4 25 | $21.8M | $30.3M | ||
| Q3 25 | $22.2M | $29.7M | ||
| Q2 25 | $24.1M | $21.4M | ||
| Q1 25 | $21.9M | $89.0M | ||
| Q4 24 | $16.0M | $21.2M | ||
| Q3 24 | $15.4M | $24.2M | ||
| Q2 24 | $11.8M | $22.3M | ||
| Q1 24 | $10.7M | $15.6M |
净利润ISSCRGNX
| Q4 25 | $4.1M | $-67.1M | ||
| Q3 25 | $7.1M | $-61.9M | ||
| Q2 25 | $2.4M | $-70.9M | ||
| Q1 25 | $5.3M | $6.1M | ||
| Q4 24 | $736.2K | $-51.2M | ||
| Q3 24 | $3.2M | $-59.6M | ||
| Q2 24 | $1.6M | $-53.0M | ||
| Q1 24 | $1.2M | $-63.3M |
毛利率ISSCRGNX
| Q4 25 | 54.5% | — | ||
| Q3 25 | 63.2% | — | ||
| Q2 25 | 35.5% | — | ||
| Q1 25 | 51.4% | — | ||
| Q4 24 | 41.4% | 70.2% | ||
| Q3 24 | 55.4% | 48.8% | ||
| Q2 24 | 53.4% | 52.5% | ||
| Q1 24 | 52.0% | 72.6% |
营业利润率ISSCRGNX
| Q4 25 | 28.9% | -190.0% | ||
| Q3 25 | 37.0% | -176.3% | ||
| Q2 25 | 14.6% | -296.3% | ||
| Q1 25 | 31.8% | 13.6% | ||
| Q4 24 | 8.4% | -242.1% | ||
| Q3 24 | 28.4% | -256.6% | ||
| Q2 24 | 17.3% | -251.3% | ||
| Q1 24 | 15.3% | -408.8% |
净利率ISSCRGNX
| Q4 25 | 18.6% | -221.3% | ||
| Q3 25 | 32.0% | -208.3% | ||
| Q2 25 | 10.1% | -331.8% | ||
| Q1 25 | 24.3% | 6.8% | ||
| Q4 24 | 4.6% | -241.3% | ||
| Q3 24 | 20.7% | -246.3% | ||
| Q2 24 | 13.2% | -237.7% | ||
| Q1 24 | 11.3% | -405.4% |
每股收益（稀释后）ISSCRGNX
| Q4 25 | $0.22 | $-1.30 | ||
| Q3 25 | $0.40 | $-1.20 | ||
| Q2 25 | $0.14 | $-1.38 | ||
| Q1 25 | $0.30 | $0.12 | ||
| Q4 24 | $0.04 | $-0.99 | ||
| Q3 24 | $0.18 | $-1.17 | ||
| Q2 24 | $0.09 | $-1.05 | ||
| Q1 24 | $0.07 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $8.3M | $230.1M |
| 总债务越低越好 | $23.8M | — |
| 股东权益账面价值 | $68.7M | $102.7M |
| 总资产 | $109.9M | $453.0M |
| 负债/权益比越低杠杆越低 | 0.35× | — |
8季度趋势，按日历期对齐
现金及短期投资ISSCRGNX
| Q4 25 | $8.3M | $230.1M | ||
| Q3 25 | $2.7M | $274.2M | ||
| Q2 25 | $601.8K | $323.3M | ||
| Q1 25 | $1.2M | $267.9M | ||
| Q4 24 | $604.6K | $234.7M | ||
| Q3 24 | $539.0K | $255.5M | ||
| Q2 24 | $521.0K | $290.4M | ||
| Q1 24 | $574.1K | $338.7M |
总债务ISSCRGNX
| Q4 25 | $23.8M | — | ||
| Q3 25 | $24.4M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益ISSCRGNX
| Q4 25 | $68.7M | $102.7M | ||
| Q3 25 | $64.6M | $161.5M | ||
| Q2 25 | $56.8M | $213.7M | ||
| Q1 25 | $53.5M | $274.2M | ||
| Q4 24 | $47.8M | $259.7M | ||
| Q3 24 | $46.6M | $301.4M | ||
| Q2 24 | $43.2M | $348.3M | ||
| Q1 24 | $41.4M | $390.7M |
总资产ISSCRGNX
| Q4 25 | $109.9M | $453.0M | ||
| Q3 25 | $103.4M | $525.2M | ||
| Q2 25 | $91.8M | $581.0M | ||
| Q1 25 | $89.9M | $490.9M | ||
| Q4 24 | $81.3M | $466.0M | ||
| Q3 24 | $82.4M | $519.1M | ||
| Q2 24 | $59.8M | $569.4M | ||
| Q1 24 | $57.6M | $629.2M |
负债/权益比ISSCRGNX
| Q4 25 | 0.35× | — | ||
| Q3 25 | 0.38× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $8.2M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $7.0M | $-52.8M |
| 自由现金流率自由现金流/营收 | 32.3% | -174.0% |
| 资本支出强度资本支出/营收 | 5.1% | 1.7% |
| 现金转化率经营现金流/净利润 | 2.01× | — |
| 过去12个月自由现金流最近4个季度 | $12.3M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流ISSCRGNX
| Q4 25 | $8.2M | $-52.3M | ||
| Q3 25 | $3.0M | $-56.0M | ||
| Q2 25 | $7.2M | $-49.3M | ||
| Q1 25 | $1.3M | $33.6M | ||
| Q4 24 | $1.8M | $-31.6M | ||
| Q3 24 | $445.3K | $-40.5M | ||
| Q2 24 | $934.1K | $-45.5M | ||
| Q1 24 | $201.1K | $-55.5M |
自由现金流ISSCRGNX
| Q4 25 | $7.0M | $-52.8M | ||
| Q3 25 | $2.0M | $-56.5M | ||
| Q2 25 | $3.5M | $-49.7M | ||
| Q1 25 | $-267.7K | $32.6M | ||
| Q4 24 | $1.6M | $-32.7M | ||
| Q3 24 | $299.5K | $-40.9M | ||
| Q2 24 | $730.8K | $-46.0M | ||
| Q1 24 | $75.4K | $-56.0M |
自由现金流率ISSCRGNX
| Q4 25 | 32.3% | -174.0% | ||
| Q3 25 | 8.8% | -189.9% | ||
| Q2 25 | 14.6% | -232.8% | ||
| Q1 25 | -1.2% | 36.6% | ||
| Q4 24 | 9.9% | -154.2% | ||
| Q3 24 | 1.9% | -168.9% | ||
| Q2 24 | 6.2% | -206.2% | ||
| Q1 24 | 0.7% | -358.5% |
资本支出强度ISSCRGNX
| Q4 25 | 5.1% | 1.7% | ||
| Q3 25 | 4.5% | 1.7% | ||
| Q2 25 | 15.3% | 1.8% | ||
| Q1 25 | 7.1% | 1.2% | ||
| Q4 24 | 1.6% | 5.1% | ||
| Q3 24 | 0.9% | 1.3% | ||
| Q2 24 | 1.7% | 2.1% | ||
| Q1 24 | 1.2% | 3.6% |
现金转化率ISSCRGNX
| Q4 25 | 2.01× | — | ||
| Q3 25 | 0.42× | — | ||
| Q2 25 | 2.95× | — | ||
| Q1 25 | 0.24× | 5.53× | ||
| Q4 24 | 2.50× | — | ||
| Q3 24 | 0.14× | — | ||
| Q2 24 | 0.60× | — | ||
| Q1 24 | 0.17× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ISSC
| Products | $13.6M | 62% |
| Services | $8.2M | 38% |
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
